Table 4.
Fecal BAs profiles of mice in Experiment 2.
| Variable (nmol/g) | LPSa | GSP + LPS | Gly + GSP + LPS | p -value |
|---|---|---|---|---|
| Total BA | 685, 39.9 | 612, 40.7 | 653, 49.9 | 0.51 |
| Unconjugated BA | 670, 39.5 | 600, 40.1 | 637, 49.3 | 0.53 |
| Conjugated BA | 15.0, 1.13ab | 12.5, 0.84b | 16.2, 1.50a | 0.10 |
| Cholic acid | 86.2, 11.2 | 68.0, 9.79 | 79.0, 12.1 | 0.51 |
| Chenodeoxycholic acid | 6.68, 0.98c | 24.1, 1.42b | 12.4, 1.00a | <0.01 |
| ω-muricholic acid | 232, 27.3 | 189, 30.3 | 202, 31.0 | 0.59 |
| α-muricholic acid | 85.1, 8.66 | 67.2, 6.17 | 71.2, 6.82 | 0.22 |
| β-muricholic acid | 106, 11.0 | 115, 12.6 | 128, 13.5 | 0.47 |
| Deoxycholic acid | 113, 9.68 | 86.7, 10.6 | 91.2, 10.7 | 0.17 |
| Lithocholic acid | 10.3, 0.97c | 24.1, 2.46a | 17.0, 1.66b | <0.01 |
| Ursodeoxycholic acid | 7.27, 0.78 | 9.12, 1.06 | 8.28, 1.14 | 0.44 |
| Taurocholic acid | 4.17, 0.58 | 2.81, 0.44 | 4.79, 0.88 | 0.12 |
| Taurochenodeoxycholic acid | 0.14, 0.04b | 0.25, 0.04a | 0.19, 0.02ab | 0.09 |
| Tauro-ω-muricholic acid | 4.02, 0.55a | 3.73, 0.48b | 4.21, 0.59b | 0.82 |
| Tauro-α-muricholic acid | 3.87, 0.50a | 3.33, 0.36b | 4.05, 0.49b | 0.52 |
| Tauro-β-muricholic acid | 0.05, 0.01b | 0.06, 0.01ab | 0.07, 0.01a | 0.08 |
| Taurodeoxycholic acid | 0.57, 0.07 | 0.48, 0.07 | 0.46, 0.06 | 0.52 |
| Taurolithocholic acid | 0.12, 0.01 | 0.17, 0.03 | 0.15, 0.01 | 0.20 |
| Tauroursodeoxycholic acid | 0.11, 0.02 | 0.13, 0.01 | 0.12, 0.01 | 0.40 |
a−c
In each row, means with the same letter represented no significant differences.
aLPS, a LPS injection group that oral gavaged with physiological saline before i.p. LPS injection. GSP + LPS, a GSP administration group that oral gavaged with 250 mg/kg GSP before i.p. LPS injection; Gly + GSP + LPS, the GSP+LPS group coupled with a dose of 10 mg/kg BW glycine-β-muricholic acid before i.p. LPS injection. n = 6–8.
BA, bile acid.